Citigroup’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-325,000
| Closed | -$136M | – | 6500 |
|
|
2025
Q3 | $136M | Buy |
325,000
+312,500
| +2,500% | +$105M | 0.06% | 301 |
|
|
2025
Q2 | $3.59M | Buy |
+12,500
| New | +$3.74M | ﹤0.01% | 2160 |
|
|
2024
Q2 | – | Sell |
-309,300
| Closed | -$71.1M | – | 5794 |
|
|
2024
Q1 | $71.1M | Buy |
+309,300
| New | +$69.8M | 0.05% | 358 |
|
|
2022
Q4 | – | Sell |
-47,000
| Closed | -$9.84M | – | 5969 |
|
|
2022
Q3 | $9.84M | Buy |
+47,000
| New | +$10.5M | 0.01% | 1149 |
|
|
2021
Q1 | – | Sell |
-800
| Closed | -$121K | – | 7438 |
|
|
2020
Q4 | $121K | Sell |
800
-6,500
| -89% | -$853K | ﹤0.01% | 5387 |
|
|
2020
Q3 | $737K | Sell |
7,300
-12,500
| -63% | -$1.37M | ﹤0.01% | 3541 |
|
|
2020
Q2 | $2.4M | Buy |
19,800
+6,800
| +52% | +$765K | ﹤0.01% | 2611 |
|
|
2020
Q1 | $1.23M | Buy |
13,000
+10,700
| +465% | +$1.02M | ﹤0.01% | 2947 |
|
|
2019
Q4 | $203K | Sell |
2,300
-600
| -21% | -$52.8K | ﹤0.01% | 5163 |
|
|
2019
Q3 | $231K | Sell |
2,900
-17,300
| -86% | -$1.39M | ﹤0.01% | 5044 |
|
|
2019
Q2 | $1.58M | Buy |
20,200
+3,200
| +19% | +$299K | ﹤0.01% | 3117 |
|
|
2019
Q1 | $2M | Buy |
17,000
+10,400
| +158% | +$1.21M | ﹤0.01% | 2646 |
|
|
2018
Q4 | $719K | Sell |
6,600
-500
| -7% | -$58K | ﹤0.01% | 3736 |
|
|
2018
Q3 | $908K | Buy |
7,100
+3,300
| +87% | +$408K | ﹤0.01% | 3601 |
|
|
2018
Q2 | $430K | Sell |
3,800
-1,300
| -25% | -$143K | ﹤0.01% | 4272 |
|
|
2018
Q1 | $573K | Sell |
5,100
-4,200
| -45% | -$534K | ﹤0.01% | 3846 |
|
|
2017
Q4 | $1.38M | Sell |
9,300
-7,300
| -44% | -$928K | ﹤0.01% | 3019 |
|
|
2017
Q3 | $1.95M | Buy |
16,600
+9,500
| +134% | +$1.21M | ﹤0.01% | 2692 |
|
|
2017
Q2 | $921K | Sell |
7,100
-5,700
| -45% | -$711K | ﹤0.01% | 3403 |
|
|
2017
Q1 | $1.73M | Sell |
12,800
-1,000
| -7% | -$151K | ﹤0.01% | 2630 |
|
|
2016
Q4 | $1.98M | Sell |
13,800
-300
| -2% | -$38.3K | ﹤0.01% | 2957 |
|
|
2016
Q3 | $1.67M | Sell |
14,100
-2,300
| -14% | -$276K | ﹤0.01% | 2690 |
|
|
2016
Q2 | $1.74M | Buy |
16,400
+4,900
| +43% | +$547K | ﹤0.01% | 2438 |
|
|
2016
Q1 | $1.28M | Buy |
11,500
+3,200
| +39% | +$405K | ﹤0.01% | 3042 |
|
|
2015
Q4 | $1.3M | Buy |
8,300
+1,600
| +24% | +$233K | ﹤0.01% | 2850 |
|
|
2015
Q3 | $879K | Sell |
6,700
-1,100
| -14% | -$176K | ﹤0.01% | 3212 |
|
|
2015
Q2 | $1.36M | Buy |
7,800
+7,600
| +3,800% | +$1.37M | ﹤0.01% | 2899 |
|
|
2015
Q1 | $34K | Buy |
+200
| New | +$30.5K | ﹤0.01% | 5770 |
|
|
2014
Q1 | – | Sell |
-1,500
| Closed | -$170K | – | 7219 |
|
|
2013
Q4 | $170K | Sell |
1,500
-1,800
| -55% | -$162K | ﹤0.01% | 4801 |
|
|
2013
Q3 | $260K | Sell |
3,300
-7,400
| -69% | -$541K | ﹤0.01% | 3943 |
|
|
2013
Q2 | $704K | Buy |
+10,700
| New | +$689K | ﹤0.01% | 3188 |
|
Other funds holding UTHR
ACA
VPM
VCM
Citigroup's UTHR Position: Q1 2026 in Review
Citigroup increased its United Therapeutics (UTHR) stake by 28% in Q1 2026, buying an estimated $25.5M and bringing the position to 235,620 shares worth $140M. The position accounts for 0.06% of the portfolio, ranked #298.
Citigroup first reported a position in UTHR in Q2 2013 and has held it in 52 quarters since. The position peaked at $518M in Q2 2024. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.
- Citigroup held 235,620 shares of United Therapeutics worth $140M as of Q1 2026.
- Citigroup bought 51,212 United Therapeutics shares in Q1 2026, an estimated $25.5M.
- United Therapeutics made up 0.06% of Citigroup's portfolio in Q1 2026, its #298 holding.
- Citigroup first reported a position in United Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Citigroup's United Therapeutics position peaked at $518M in Q2 2024.
- 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.